Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026)
Tg Therapeutics' (TGTX) quarterly Income from Continuing Operations came in at 19763000.0 in Q1 2026, up 289.96% year-on-year from 5068000.0 in Q1 2025, and down 15.65% quarter-over-quarter from 23431000.0 in Q4 2025.
Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Tg Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 19763000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 289.96% year-over-year to 19763000.0 in Q1 2026; TTM through Mar 2026 was 462276000.0, a 879.92% increase from a year earlier, with the FY2025 full-year figure at 447528000.0, up 1323.44% from the prior year.
- Income from Continuing Operations declined to 19763000.0 in Q1 2026 per TGTX's latest filing, from 23431000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 390895000.0 in Q3 2025 and bottomed at 83822000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 3868000.0 (2024), against an average of 15079882.35.
- Across the five-year window, Income from Continuing Operations plunged 96.6% in 2024 and surged 10005.87% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 83822000.0 in 2022, then jumped by 84.1% to 13326000.0 in 2023, then surged by 335.54% to 31388000.0 in 2024, then decreased by 25.35% to 23431000.0 in 2025, then declined by 15.65% to 19763000.0 in 2026.
- Per Business Quant, the three latest TGTX Income from Continuing Operations figures stand at 19763000.0 (Q1 2026), 23431000.0 (Q4 2025), and 390895000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Tg Therapeutics | 8.08 Bn | 8.00 Bn | 171.41 Mn | 19.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.76 Mn |
| Dec 31, 2025 | 23.43 Mn |
| Sep 30, 2025 | 390.90 Mn |
| Jun 30, 2025 | 28.19 Mn |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 31.39 Mn |
| Sep 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 6.85 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -13.33 Mn |
| Sep 30, 2023 | 113.93 Mn |
| Jun 30, 2023 | -47.61 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -83.82 Mn |
| Sep 30, 2022 | -40.96 Mn |
| Jun 30, 2022 | -56.23 Mn |
| Mar 31, 2022 | -75.13 Mn |
| Dec 31, 2021 | -95.89 Mn |
| Sep 30, 2021 | -103.17 Mn |
| Jun 30, 2021 | -84.35 Mn |